99% Savings - Buy Just @1 Rs X
Roczid 250 Injection is a prescription medicine that is available as a Injection. It is typically used for the treatment of Skin Infections, Pneumonia. Secondary and off-label uses of Roczid 250 Injection have also been mentioned below.
The right dosage of Roczid 250 Injection depends on the age, gender, and medical history of the patient. Individual symptoms and route of administration also determines the right dosage. Detailed information has been provided in the dosage section.
While these are the most often observed Roczid 250 Injection side effects, there are can be others also. These have been listed below. Normally, these side effects of Roczid 250 Injection are not long lasting and go away when the treatment is finished. Consult your doctor if these side effects become worse or stay for a longer duration.
It is also important to note that Roczid 250 Injection has a Safe effect for pregnant women and Safe effect on lactating mothers. Warnings related to Roczid 250 Injection's effects on the liver, heart and kidney, if any, have been listed below.
Roczid 250 Injection is not recommended if you suffer from certain medical conditions as it can have adverse effects. Kidney Disease are examples of such conditions. Some other conditions that can be affected by Roczid 250 Injection are listed in the contraindications section below.
Besides this, Roczid 250 Injection may also have severe interaction with some medicines. Refer to the list below for further details.
In addition to the above precautions for Roczid 250 Injection, it is important to know that it is not safe while driving, and is not habit-forming.
Roczid 250 Injection is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
13 - 18 years (Adolescent) |
|
2 - 12 years (Child) |
|
Infant (1 month to 2 years) |
|
Neonates (0 to 1 month) |
|
Is the use of Roczid 250 Injection safe for pregnant women?
Pregnant women can take Roczid safely.
Is the use of Roczid 250 Injection safe during breastfeeding?
Roczid is safe for breastfeeding women.
What is the effect of Roczid 250 Injection on the Kidneys?
Very few cases of side effects of Roczid on kidney have been reported.
What is the effect of Roczid 250 Injection on the Liver?
Roczid is not harmful for the liver.
What is the effect of Roczid 250 Injection on the Heart?
Roczid is not harmful for the heart.
If you are suffering from any of the following diseases, you should not take Roczid 250 Injection unless your doctor advises you to do so -
Is this Roczid 250 Injection habit forming or addictive?
Roczid 250 Injection is not addictive in nature.
Is it safe to drive or operate heavy machinery when consuming?
No, you should do not do anything that requires concentration and attention as the Roczid 250 Injection can make you feel drowsy.
Is it safe?
Roczid 250 Injection is safe but it is important to consult a doctor before taking it.
Is it able to treat mental disorders?
There is no benefit of taking Roczid 250 Injection for mental disorders.
Interaction between Food and Roczid 250 Injection
It is safe to take Roczid 250 Injection with food.
Interaction between Alcohol and Roczid 250 Injection
It is difficult to say anything about the effect of Roczid 250 Injection and alcohol. No research has been done on this yet.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; FORTAZ® (ceftazidime)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-312